ArticleJHEP reports : innovation in hepatology2025

Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies.

Richard S Finn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.